Related Experiment Video
Updated: Feb 9, 2026
09:00
Use of the Protease Fluorescent Detection Kit to Determine Protease Activity
Published on: August 4, 2009
28.9K
Rheumatic Disease: Protease-Activated Receptor-2 in Synovial Joint Pathobiology
Kendal McCulloch1, Sarah McGrath2, Carmen Huesa1
1Institute of Biomedical & Environmental Health Research, University of the West of Scotland, Paisley, United Kingdom.
Frontiers in Endocrinology
|June 8, 2018
Summary
Protease-activated receptor-2 (PAR2) plays a key role in rheumatic diseases like rheumatoid arthritis and osteoarthritis. Inhibiting PAR2 may reduce joint inflammation and degradation, offering a potential therapeutic target.
Area of Science:
- Rheumatology
- Molecular Biology
- Immunology
Background:
- Protease-activated receptor-2 (PAR2) is a G-protein-coupled receptor activated by serine proteases.
- PAR2 has emerged as a significant factor in the pathophysiology of rheumatoid arthritis (RA) and osteoarthritis (OA).
Purpose of the Study:
- To review the role of PAR2 in rheumatic diseases.
- To explore PAR2 as a therapeutic target for joint pain and degradation.
Main Methods:
- Review of existing literature on PAR2 function in animal models of RA and OA.
- Analysis of studies demonstrating the effects of PAR2 absence or inhibition on inflammatory and destructive processes.
Main Results:
- PAR2 contributes to pro-inflammatory and destructive processes in both RA and OA.
- Absence of PAR2 significantly reduces synovitis, cartilage degradation, and bone erosion in murine models of RA.
- PAR2 disruption protects against cartilage degradation, subchondral bone osteosclerosis, and osteophyte formation in experimental OA models.
Conclusions:
- PAR2 is implicated in the pathogenesis of rheumatic diseases.
- Targeting PAR2 presents a promising therapeutic strategy for managing pain and joint destruction in RA and OA.
Related Concept Videos
01:16Structural Joints: Synovial Joints
7.1K
Synovial joints are the most common type of joint in the body. A key structural characteristic for a synovial joint is the presence of a joint cavity. This fluid-filled space is where the articulating surfaces of the bones contact each other. Also, unlike fibrous or cartilaginous joints, the articulating bone surfaces at a synovial joint are not directly connected to each other with fibrous connective tissue or cartilage. This gives the bones of a synovial joint the ability to move smoothly...
7.1K
01:07Development of the Limb Synovial Joints
2.4K
Joints form during embryonic development in conjunction with the formation and growth of the associated bones. The embryonic tissue that gives rise to all bones, cartilage, and connective tissues of the body is called mesenchyme.
The mesenchymal stem cells differentiate into chondrocytes that form the hyaline cartilage, and later the cartilaginous model of the bone. This model further transforms into a bone. This process is known as endochondral ossification.
During development, the limbs...
The mesenchymal stem cells differentiate into chondrocytes that form the hyaline cartilage, and later the cartilaginous model of the bone. This model further transforms into a bone. This process is known as endochondral ossification.
During development, the limbs...
2.4K
01:23Rheumatic Heart Disease I: Introduction
541
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
541
01:20Rheumatic Heart Disease IV: Nursing Management
342
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
342
01:21Rheumatic Heart Disease III: Medical Management
371
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
371
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
635
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
635